Suresnes, France, April 23, 2026 – Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share. The acquisition strengthens Servier’s leadership in low-grade glioma and expands the Group’s position in oncology with the addition of a marketed product and pipeline focused on rare cancers.
This acquisition represents a significant step forward for Servier as part of our 2030 ambition to strengthen our position in rare cancers, and more specifically in pediatric low-grade glioma. Integrating Day One’s scientific and clinical capabilities will enhance our Group’s ability to support long-term innovation and translate science into meaningful medicines for children and families affected by rare cancers.
Olivier Laureau, President of Servier
Day One’s portfolio includes OJEMDATM (tovorafenib), an FDA-approved medicine in pediatric low-grade glioma, the most common form of childhood brain tumor. Day One already markets the product in the United States and has licensed the rights outside the U.S. to Ipsen.
The transaction also strengthens Servier’s oncology pipeline from early clinical to Phase 3. In addition to tovorafenib, which is being investigated in additional indications, Day One’s pipeline includes Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate (ADC) and DAY301, a targeted therapy in rare cancers.
Welcoming Day One to Servier marks an important next chapter in how we are expanding our presence in oncology in the U.S. and strengthening our ability to deliver for patients. Day One is joining us with strong science, an approved medicine, and a team that knows how to turn innovation into real outcomes for patients. This is about combining focus with execution to deliver for patients with rare cancers.
David K. Lee, Executive Vice President, USA, and CEO, Servier Pharmaceuticals
Completion of Tender Offer and Transaction Details
The tender offer expired at one minute past 11:59 p.m., Eastern Time, on April 22, 2026, and was not further extended following satisfaction of the minimum tender condition and the other offer conditions. Promptly following the foregoing expiration, Servier accepted tendered shares for payment of the Offer Price.
Following its acceptance of the tendered shares, Servier Detroit Inc., a direct wholly owned subsidiary of Servier Pharmaceuticals LLC (“Parent”), which is an indirect wholly owned subsidiary of Servier S.A.S., will promptly merge with and into Day One (the “Merger”). At the effective time of the Merger, each outstanding share of common stock of Day One that has not been validly tendered (other than shares owned by Day One or Servier or by any Day One stockholders who properly perfected their appraisal rights under the DGCL – Delaware General Corporation Law) will be converted automatically into the right to receive the Offer Price. As a result of the Merger, Day One will become a wholly owned subsidiary of Parent. With completion of the Merger, the transaction will represent a total equity value of approximately $2.5 billion.
Following the close of trading on The Nasdaq Stock Market LLC (“Nasdaq”) on April 22, 2026, all shares of Day One common stock ceased trading on Nasdaq, and Servier intends promptly to cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.
Cautionary Notice Regarding Forward-Looking Statements & Additional Information about the Acquisition and Where to Find It can be found in the press release